Home > Back to Publisher > Report Information

Pharmaceutical Pricing, Reimbursement, and Market Access News in the Third Quarter of 2011

Decision Resources
November 1, 2011
SKU: DECR6693896

Abstract Table of Contents Related Reports

Countries covered: Japan, United States, Europe

In the third quarter of 2011, politicians in the United States, Europe, and Japan faced the unpleasant task of having to make substantial budget cuts. Healthcare spending was a major target for cost cutting, and further economies can be expected in the coming months.

Please note, the PDF e-mail from publisher version of this report is for a global site license.

Executive Summary: Strategic Considerations; Stakeholder Implications
Overview
United States: Health Insurance Trends; Drug Benefit Trends; Struggle to Reduce the Budget Deficit; Healthcare Reform Legislation Referred to the Supreme Court; Renewed Criticism of Authorized Generics; Insurers to Supply Data to New Health Care Cost Institute
France: Legislation to Reform the French Regulatory System; New Cost-Containment Measures Proposed for 2012
Germany: Challenges Presented by the Pharmaceutical Restructuring Act; Burden of Increased Mandatory Rebates on Leading Manufacturers; Revised IQWiG Methodology for Benefit Assessment; Limited Substitution of Certain Biosimilars
Italy: Market Trends
Spain: Government Pledge to Tackle Healthcare Budget Deficit; New Cost-Containment Measures; Creation of a New Cost-Effectiveness Committee
United Kingdom: Government Response to the Public Consultation on Value-Based Pricing; Market Trends; Industry Call for Greater Use of Real-World Data to Demonstrate Value; Government Pledge to Publish Key NHS Data
Japan: Prospect of General Spending Cuts to Pay for Reconstruction; Planning for the April 2012 Biennial Price Revision; Premium for the Development of New Drugs and Elimination of Off-Label Drug Use; Price Cuts for Long-Listed Drugs; Repricing in Response to Market Expansion; Lower Prices for Generics
Outlook and Implications for the Pharmaceutical Industry
Tables: 1. Hypothetical Examples of the Impact on Prices of Japan’s Premium for the; Development of New Drugs and Elimination of Off-Label Drug Use
Figures: 1. Health Insurance Coverage of the Total U.S. Population, 1999-2010; 2. Health Insurance Coverage of the Nonelderly U.S. Population, 1999-2010; 3. Health Insurance Coverage of the Elderly U.S. Population, 1999-2010; 4. Percentage of U.S. Employers Sponsoring Employee Health Benefits, 1999-2011; 5. Percentage of U.S. Covered Workers in Formulary Designs of Various Structures,; 2000-2011; 6. Average Copayments in the United States by Formulary Tier, 2000-2011; 7. Average Coinsurance Rates in the United States by Formulary Tier, 2000-2011; 8. U.S. Employers’ Use of Common Utilization Management Tools, 2007-2011; 9. U.S. Employers’ Use of Common Clinical and Educational Programs, 2007-2011; 10. U.S. Employers’ Use of Value-Based Benefit Design Tools, 2009-2011; 11. U.S. Employers’ Strategies for Managing the Specialty Pharmacy Benefit, 2010-2011; 12. French National Targets for Health Insurance Spending Growth and; Pharmaceutical Spending Growth, 1999-2012; 13. Generics’ Share of the Italian Pharmaceutical Market, 2001-2009; 14. Average Net Ingredient Cost Per Prescription Item in England, 2000-2010; 15. Generics’ Share of the English Pharmaceutical Market, 1997-2010

More Europe Pricing Reports

Pricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure by GBI Research
Pricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure Summary GBI Research, the leading business intelligence provider, ...

The Outlook for Pharmaceuticals in Central & Eastern Europe (pdf/xls) by Espicom Healthcare Intelligence
The pharmaceutical market of Central & Eastern Europe is estimated at US$63.6 billion at retail prices in 2011; it is expected to reach US$104.2 billion ...

The Outlook for Pharmaceuticals in Northern Europe (pdf/xls) by Espicom Healthcare Intelligence
The Northern European countries are projected to represent a combined pharmaceutical market value of over US$26 billion at retail prices by 2016. ...

The Pharmaceutical Market: Czech Republic (pdf/xls) by Espicom Healthcare Intelligence
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting ...

The Pharmaceutical Market: Hungary (pdf/xls) by Espicom Healthcare Intelligence
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting ...

See all reports like this >>

More Europe Reports

A Comprehensive Study Of The UK Video Conferencing Equipment Market In 2010, Rating & Valuing Each Of The 30 Companies That Operate In Today's Market by Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...

A Comprehensive Study Of The UK Tableware Market In 2010, Rating & Valuing Each Of The 166 Companies That Operate In Today's Market by Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...

A Comprehensive Study Of The UK Surveyors & Valuers Market In 2010, Rating & Valuing Each Of The 943 Companies That Operate In Today's Market by Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...

A Comprehensive Study Of The UK Subsea Engineering Market In 2010, Rating & Valuing Each Of The 142 Companies That Operate In Today's Market by Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...

A Comprehensive Study Of The UK Structural Engineering Consultancy Market In 2010, Rating & Valuing Each Of The 300 Companies That Operate In Today's Market by Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...

See all reports like this >>

Pharmaceutical Pricing, Reimbursement, and Market Access News in the Third Quarter of 2011

Share this report

Other tasks

Research Assistance

Related Markets

Pricing Reports

Free Alert Me service